1019 US Highway 202-206, Building K
NJ Center of Excellence
About Nevakar, LLCNevakar is a specialty pharmaceutical company, focused on developing innovative products in injectable and ophthalmic space.
Our goal is to develop enhanced products that address unmet clinical and/or commercial needs of currently [FDA] approved molecules, through intensive R&D and clinical efforts.
These drug repositioning efforts are focused on:
1. Developing novel or improved formulation 2. Designing an improved and functional packaging 3. Novel drug delivery approaches 4. Regulatory and clinical strategies
Resulting new and repositioned products are expected to provide patient centric benefits, while ensuring incremental value proposition for the healthcare system.
These new products with proprietary enhancements are filed with FDA, primarily under 505(b)(2) regulatory pathway.
Nevakar’s business model is supported by state of the art R&D infrastructure, located in NJ Center of Excellence, and a well experienced management and leadership team.
CEO: Navneet Puri, PhD
COO: Sriram Ramanathan, MS, MBA
14 articles with Nevakar, LLC
Vyluma Inc. Launches With Robust Opthalmic Portfolio, Leading With A Pharmaceutical Treatment In Phase III For Myopia
Vyluma Inc. announces its establishment as a wholly owned subsidiary of Nevakar Inc., focusing on pharmaceutical ophthalmic solutions.
Nevakar Inc., a privately held biopharmaceutical company, announces the establishment of Nevakar Injectables Inc., a newly formed company with an established portfolio of products focused on critical patient care, acute pain management, long acting injectables and hospital infections.
Nevakar Inc., a privately held biopharmaceutical company, announces the establishment of Vyluma Inc., a newly formed company with a focus on the development and commercialization of therapies to treat ophthalmic diseases.
Nevakar and Théa Enter into Licensing Agreement for the Commercialization of NVK-002 (Atropine for the Treatment of the Progression of Myopia in Children) in Europe
Nevakar Inc. (“Nevakar”), a biopharmaceutical company developing multiple assets in the ophthalmic and injectable areas, and Laboratoires Théa (“Théa”) announced today that they recently entered into an exclusive licensing agreement for the commercialization of NVK-002 in Europe.
Zhaoke Ophthalmology Announced First Patient Completes Three Year Enrollment in Phase III CHAMP Study of NVK-002
Zhaoke Ophthalmology Pharmaceutical Ltd. is pleased to announce that the first patient has completed three year enrollment in the Phase III CHAMP study carried out by its partner, Nevakar Inc.
First Patient Completes Three Year Enrollment in Nevakar’s Phase III CHAMP Study of NVK-002 Evaluating Low-Dose Atropine Ophthalmic Solution for the Treatment of Myopia in Children
Key Step Forward in Developing a Potential First-to-Market Pharmacologic Treatment for Myopia in Children
Nevakar Inc., a biopharmaceutical company developing multiple assets in the ophthalmic and injectable areas, announced it received approval from the U.S. Food and Drug Administration to market Ephedrine Sulfate Injection in a ready-to-use 50mg/10 ml single use vial presentation.
Nevakar and Zhaoke Ophthalmology Enter into Licensing Agreement for NVK-002 (Atropine for the Treatment of the Progression of Myopia in Children)
Nevakar Inc. and Zhaoke Ophthalmology Pharmaceutical Ltd. announced that they have recently entered into an exclusive licensing agreement for the development and commercialization of Nevakar’s NVK-002 in Greater China, South Korea and the Southeast Asian territories.
Nevakar Enters into $17.5 Million Product Financing Agreement with H.I.G. Capital Partners for Continued Development of Injectable Products
Nevakar Inc. announced that it has entered into a $17.5 million product financing agreement with an affiliate of H.I.G.
If Approved, NVK-002 will be the First Global Pharmacologic Treatment to Slow the Progression of Myopia in Children
Nevakar Announces First Subject Dosed in its Phase III Clinical Trial of NVK-002 for the Treatment of Myopia in Children
If successful in Phase III and then in obtaining approval from the FDA, NVK-002 would represent the first pharmacologic eye drop for this patient population.